SGMO Sangamo Therapeutics Inc

Price (delayed)

$1.16

Market cap

$205.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$182.68M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
SGMO's debt is down by 12% YoY and by 3.8% QoQ
The quick ratio rose by 7% year-on-year
The gross profit has soared by 80% YoY but it fell by 8% QoQ
The revenue has soared by 80% year-on-year but it is down by 8% since the previous quarter
The equity has shrunk by 56% YoY and by 42% QoQ
Sangamo Therapeutics's net income has decreased by 40% YoY and by 26% QoQ

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
177.35M
Market cap
$205.72M
Enterprise value
$182.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
1.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.91
Earnings
Revenue
$201.42M
EBIT
-$254.05M
EBITDA
-$229.43M
Free cash flow
-$257.31M
Per share
EPS
-$1.44
Free cash flow per share
-$1.45
Book value per share
$0.76
Revenue per share
$1.14
TBVPS
$1.24
Balance sheet
Total assets
$219.7M
Total liabilities
$84.78M
Debt
$34.98M
Equity
$134.92M
Working capital
$99.09M
Liquidity
Debt to equity
0.26
Current ratio
3.04
Quick ratio
2.78
Net debt/EBITDA
0.1
Margins
EBITDA margin
-113.9%
Gross margin
100%
Net margin
-123.9%
Operating margin
-132.7%
Efficiency
Return on assets
-64.5%
Return on equity
-99.9%
Return on invested capital
-104.1%
Return on capital employed
-148.4%
Return on sales
-126.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
8.41%
1 week
5.45%
1 month
159.86%
1 year
-61.97%
YTD
113.51%
QTD
113.51%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$201.42M
Gross profit
$201.42M
Operating income
-$267.34M
Net income
-$249.51M
Gross margin
100%
Net margin
-123.9%
The gross profit has soared by 80% YoY but it fell by 8% QoQ
The revenue has soared by 80% year-on-year but it is down by 8% since the previous quarter
The operating income has contracted by 44% YoY and by 24% from the previous quarter
Sangamo Therapeutics's net income has decreased by 40% YoY and by 26% QoQ

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
1.52
P/S
1.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.91
The EPS has declined by 22% year-on-year and by 21% since the previous quarter
The equity has shrunk by 56% YoY and by 42% QoQ
The price to book (P/B) is 39% lower than the 5-year quarterly average of 2.5 but 38% higher than the last 4 quarters average of 1.1
The stock's P/S is 89% below its 5-year quarterly average of 9.0 and 43% below its last 4 quarters average of 1.8
The revenue has soared by 80% year-on-year but it is down by 8% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The company's return on assets has shrunk by 135% YoY and by 56% QoQ
Sangamo Therapeutics's return on invested capital has shrunk by 105% YoY and by 48% QoQ
The ROE has plunged by 88% YoY and by 48% from the previous quarter
The return on sales has declined by 35% since the previous quarter but it is up by 20% year-on-year

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 159% greater than its total liabilities
SGMO's total liabilities has dropped by 70% year-on-year and by 7% since the previous quarter
SGMO's total assets has dropped by 63% year-on-year and by 32% since the previous quarter
SGMO's debt is 74% lower than its equity
Sangamo Therapeutics's debt to equity has surged by 100% YoY and by 63% QoQ
The equity has shrunk by 56% YoY and by 42% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.